What is the next step in management for a patient with acute lymphoblastic leukemia who relapses during chemotherapy?

Management of Acute Lymphoblastic Leukemia Relapsing During Chemotherapy

For patients with acute lymphoblastic leukemia who relapse while on chemotherapy, immediately pursue blinatumomab or inotuzumab ozogamicin as second-line therapy (not re-treatment with the same chemotherapy), followed by allogeneic hematopoietic stem cell transplantation once remission is achieved. 1, 2

Treatment Algorithm Based on Relapse Timing

Early Relapse (<36 months from diagnosis)

• Do NOT re-treat with the same induction regimen - this is only appropriate for late relapses (≥36 months) 1
• Proceed directly to immunotherapy-based salvage

Preferred Second-Line Options

For B-cell precursor ALL:

1. Blinatumomab (preferred for low disease burden, preserved T-cell function) 1, 3

   • Achieves 80.7% CR/CRi rate
   • 78.4% MRD-negative rate
   • Superior in patients with lower marrow burden

2. Inotuzumab ozogamicin (preferred for high disease burden) 1, 3

   • Significantly superior to standard chemotherapy (80.7% vs 29.4% CR/CRi; P<0.001)
   • Median OS 13.9 vs 9.9 months compared to chemotherapy (P=0.005)
   • Critical caveat: Higher risk of hepatic veno-occlusive disease, especially with dual alkylator-based transplant conditioning - ensure adequate time interval before transplant 3

For T-cell ALL:

• Nelarabine-containing regimens 1

Post-Remission Consolidation Strategy

Allogeneic HSCT is mandatory for patients achieving second remission - this is not optional for early relapse 1

Key Transplant Considerations:

• MRD status before transplant predicts outcome: Patients achieving MRD-negative second remission have 3-year OS of 69% and event-free survival of 62% 1
• Response to salvage therapy is critical - aim for MRD negativity before proceeding to transplant
• For patients relapsing after first allogeneic HSCT, consider second allogeneic HSCT and/or donor lymphocyte infusion 1

Sequential Therapy Approach

Optimal sequencing for high-burden disease:

• Inotuzumab for cytoreduction → Blinatumomab for consolidation → Allogeneic HSCT 3
• This leverages inotuzumab's cytoreductive capability followed by blinatumomab's immunologic effect when T-cell function is preserved

Emerging Therapies

CAR T-cell therapy shows promising results with 88-90% complete response rates in relapsed/refractory B-cell ALL 1, 2, though this is increasingly being considered when immunotherapy fails or as part of clinical trials.

Common Pitfalls to Avoid

1. Do not re-challenge with the same chemotherapy regimen for early relapse - this is associated with poor outcomes
2. Do not delay transplant evaluation - begin donor search immediately upon starting salvage therapy
3. Monitor for veno-occlusive disease risk with inotuzumab, particularly if proceeding to transplant with alkylator-based conditioning
4. Do not skip MRD assessment - MRD status before transplant is the strongest predictor of post-transplant outcomes

Clinical Trial Participation

When available, clinical trial enrollment is preferred, particularly for patients with high-risk features or those who have failed initial immunotherapy 1, 2